Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Harbour BioMed Approved for China Phase II/III Trial of Autoimmune Candidate

publication date: Apr 15, 2020

Harbour BioMed received China IND approval to conduct a seamless Phase II/III trial of HBM9161 in patients with adult immune thrombocytopenia (ITP). HBM9161, a fully human mAb targeting the neonatal Fc receptor (FcRn), accelerates the degradation of autoantibodies that drive ITP and other autoimmune disorders. HBM., which plans to begin clinical trials of HBM9161 in several other autoimmune diseases, in-licensed greater China rights to the candidate from Korea's HanAll Biopharma. HBM is headquartered in Boston with operations in Rotterdam and Shanghai. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital